scholarly journals Progression of renal failure in patients with renal disease of diverse etiology on protein-restricted diet

1985 ◽  
Vol 27 (3) ◽  
pp. 553-557 ◽  
Author(s):  
Lamberto Oldrizzi ◽  
Carlo Rugiu ◽  
Enrico Valvo ◽  
Antonio Lupo ◽  
Carmelo Loschiavo ◽  
...  
Keyword(s):  
Renal Failure ◽  
Renal Disease ◽  
Restricted Diet ◽  
Progression Of Renal Failure ◽  
Protein Restricted Diet

scholarly journals Effects of dietary protein on renal function and lipid metabolism in five-sixths nephrectomized rats

2003 ◽  
Vol 89 (4) ◽  
pp. 491-497 ◽  
Author(s):  
Shu-Tzu Chen ◽  
Sheng-Jeng Peng ◽  
Jiun-Rong Chen
Keyword(s):  
Renal Failure ◽  
Renal Function ◽  
Lipid Metabolism ◽  
Chronic Renal Failure ◽  
Renal Disease ◽  
Dietary Protein ◽  
Casein Diet ◽  
Experimental Animals ◽  
Rate Of Progression ◽  
Progression Of Renal Failure

The objective of the present experiment was to examine the effect of substituting different quantities of soyabean protein for casein on renal function and lipid metabolism in rats with chronic renal failure induced by a five-sixths nephrectomy. Experimental animals were subjected to a nephrectomy and fed either casein or soyabean protein (200 or 100 g/kg diet). The diets were isoenergetic with identical fat, Na, K and P contents. Rats ingesting 200 g casein/kg diet showed a significantly (P<0·05) accelerated course of chronic renal failure, while the soyabean-protein groups showed retarded progression of the experimentally induced renal disease and hypercholesterolaemic effects. Rats in the low-soyabean-protein diet (100 g/kg) also demonstrated increased serum albumin and decreased serum triacylglycerol, total cholesterol concentrations and blood urea-N; however, the low-casein diet significantly (P<0·05) increased serum triacylglycerol. Results of the present study show that the replacement of casein by soyabean protein was related to the rate of progression of renal failure and improvement in lipid profiles in serum of five-sixths nephrectomized rats.

scholarly journals Effects of a protein-restricted diet upon hepatic production of glucose in chronic renal failure

1995 ◽  
Vol 35 (5) ◽  
pp. 600-601
Author(s):  
V. Blanchetier ◽  
V. Rigalleau ◽  
C. Combe ◽  
M. Aparicio ◽  
H. Gin
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Restricted Diet ◽  
Protein Restricted Diet

scholarly journals Skeletal muscle and nutritional assessment in chronic renal failure patients on a protein-restricted diet

2004 ◽  
Vol 255 (1) ◽  
pp. 115-124 ◽  
Author(s):  
A. Cupisti ◽  
R. Licitra ◽  
C. Chisari ◽  
G. Stampacchia ◽  
C. D'Alessandro ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Renal Failure ◽  
Chronic Renal Failure ◽  
Nutritional Assessment ◽  
Restricted Diet ◽  
Protein Restricted Diet

scholarly journals Erythropoietin therapy in predialysis patients

2003 ◽  
Vol 56 (11-12) ◽  
pp. 529-535 ◽  
Author(s):  
Nada Dimkovic
Keyword(s):  
Renal Failure ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hemoglobin Concentration ◽  
Cardiovascular Morbidity ◽  
Morbidity And Mortality ◽  
Cardiovascular Morbidity And Mortality ◽  
Progression Of Renal Failure ◽  
Stage Renal Disease ◽  
End Stage

Introduction Anemia is recognized as a very important non-traditional risk factor for cardiovascular morbidity and mortality in patients with uremia. Despite many advantages of erythropoietin therapy, the number of patients treated with this drug is modest, particularly during the pre-end stage renal disease. Patients with chronic renal failure are at risk to develop coronary artery disease, left ventricular hypertrophy and chronic heart failure when hemoglobin concentration falls below 10 g/dl and creatinine clearance under 60 ml/min. Erythropoietin therapy Early erythropoietin treatment prevents not only cardiovascular morbidity and mortality, but also progression of renal failure towards end-stage renal disease. Anti-oxidant, anti-hypoxic and anti-apoptotic effects of erythropoietin prevent tubular lesions and interstitial fibrosis. There still remains a confusion regarding the optimum target hemoglobin concentration in the pre-dialysis phase. Guidelines in Europe and US are probably not appropriate for all patients and it is important that renal anemia patients are considered as individuals. It may be appropriate to normalize hemoglobin concentration in young patients who have active lifestyles and no severe co-morbidity. In contrast, partial correction is more appropriate for the elderly with significant co-morbidities. Special attention should be paid to patients with diabetes, where anemia starts earlier and is more profound than in other renal patients. There is no risk of early anemia treatment using erythropoietin and this regime does not increase the total cost of treatment. Conclusion Early referral to a nephrologist is the key how to define underlying renal disease, slow down the progression of renal failure, prevent co-morbid conditions and to prepare patients for end-stage renal disease treatment.

Sign in / Sign up

Export Citation Format

Share Document